{"id":16478,"date":"2025-10-21T10:46:38","date_gmt":"2025-10-21T03:46:38","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=16478"},"modified":"2025-11-15T16:06:36","modified_gmt":"2025-11-15T09:06:36","slug":"iopromide","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/iopromide\/","title":{"rendered":"Iopromide"},"content":{"rendered":"<p><em>(Ph. Eur. monograph 1753 )<\/em><\/p>\n<p>C<sub>18<\/sub>H<sub>24<\/sub>I<sub>3<\/sub>N<sub>3<\/sub>O<sub>8<\/sub> 791 73334-07-3<\/p>\n<p><strong>Action and use<\/strong><\/p>\n<p>Iodinated contrast medium.<\/p>\n<h2>DEFINITION<\/h2>\n<p>N,N\u2032-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylbenzene-1,3-dicarboxamide.<\/p>\n<p>Mixture of diastereoisomers and atropisomers.<\/p>\n<h3>Content<\/h3>\n<p>97.0 per cent to 102.0 per cent (anhydrous substance).<\/p>\n<h2>CHARACTERS<\/h2>\n<h3>Appearance<\/h3>\n<p>White or slightly yellowish powder.<\/p>\n<h3>Solubility<\/h3>\n<p>Freely soluble in water and in dimethyl sulfoxide, practically insoluble in ethanol (96 per cent) and in acetone.<\/p>\n<h2>IDENTIFICATION<\/h2>\n<p>Infrared absorption spectrophotometry (2.2.24).<\/p>\n<h3>Iopromide<\/h3>\n<p>Comparison iopromide CRS.<\/p>\n<h2>TESTS<\/h2>\n<h3>Appearance of solution<\/h3>\n<p>The solution is clear (2.2.1) and not more intensely coloured than reference solutions BY6, B6 and Y6 (2.2.2, Method I).<\/p>\n<p>Dissolve 16.5 g in 20 mL of carbon dioxide-free water R while heating on a water-bath at a temperature not exceeding 70 \u00b0C. Allow to cool to room temperature.<\/p>\n<h3>Conductivity (2.2.38)<\/h3>\n<p>Maximum 50 \u03bcS\u00b7cm .<\/p>\n<p>Dissolve 1.000 g in water R and dilute to 50.0 mL with the same solvent.<\/p>\n<h3>Impurity A and related primary aromatic amines<\/h3>\n<p>Maximum 0.01 per cent.<\/p>\n<p>Protect the solutions from light throughout the test. All given times are critical for the test results. The test solution, reference solution and blank solution must be processed in parallel.<\/p>\n<p>Test solution: Dissolve 0.500 g of the substance to be examined in 20.0 mL of water R in a 25 mL volumetric flask.<\/p>\n<p>Reference solution: Dissolve the contents of a vial of iopromide impurity A CRS in 5.0 mL of water R. Transfer 2.0 mL of this solution to a 25 mL volumetric flask and add 18.0 mL of water R.<\/p>\n<p>Blank solution: Place 20.0 mL of water R in a 25 mL volumetric flask.<\/p>\n<p>Cool the test solution, reference solution and blank solution in a bath of iced water for 5 min. Add 1.0 mL of hydrochloric acid R1 to each solution and cool again for 5 min in a bath of iced water. Add 1.0 mL of a 20 g\/L solution of sodium nitrite R, shake vigorously and cool for another 5 min in a bath of iced water. To each solution add 0.50 mL of an 80 g\/L solution of sulfamic acid R. Over the next 5 min, shake vigorously several times, raising the stoppers to vent the gas that evolves. Afterwards, add to each solution 1.0 mL of a 1 g\/L solution of naphthylethylenediamine dihydrochloride R in a mixture of 300 volumes of water R and 700 volumes of propylene glycol R, shake, allow to cool to room temperature for 10 min and dilute to 25.0 mL with water R. Degas the solutions in an ultrasonic bath for 1 min and measure the absorbance (2.2.25) of the test solution and the reference solution at 495 nm against the blank, within 5 min. The test is not valid unless the absorbance of the reference solution is at least 0.08. The absorbance of the test solution is not greater<br \/>\nthan the absorbance of the reference solution.<\/p>\n<h3>Impurity B<\/h3>\n<p>Liquid chromatography (2.2.29).<\/p>\n<p>Solvent mixture methanol R, water R (50:50 V\/V).<\/p>\n<p>Test solution: Dissolve 40.0 mg of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (a): Dissolve 40.0 mg of iopromide CRS in the solvent mixture and dilute to 25.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (b): Introduce several millilitres of reference solution (a) into a vial sealed with a crimp-top. Heat at 121 \u00b0C for 15 min.<\/p>\n<p>Reference solution (c): Dilute 1.5 mL of the test solution to 100.0 mL with the solvent mixture.<\/p>\n<p>Column:<\/p>\n<p>\u2014 size: l = 0.25 m, \u00d8 = 4.6 mm;<\/p>\n<p>\u2014 stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 \u03bcm);<\/p>\n<p>\u2014 temperature: 20 \u00b0C.<\/p>\n<p>Mobile phase: Mix 6 g of chloroform R with 59 g of methanol R. Add 900 g of water for chromatography R in small portions to the chloroform\/methanol mixture and stir for at least 2 h to obtain a homogeneous solution.<\/p>\n<p>Flow rate: 1.2 mL\/min. Detection Spectrophotometer at 254 nm.<\/p>\n<p>Injection: 10 \u03bcL of the test solution and reference solutions (a) and (c).<\/p>\n<p>Run time: 50 min.<\/p>\n<p>Identification of impurities: Use the chromatogram supplied with iopromide CRS and the chromatogram obtained with reference solution (a) to identify the peaks due to impurity B isomers Y1 and Y2.<\/p>\n<p>Relative retention: With reference to iopromide isomer Z2 (retention time = about 34 min): impurity B isomer Y1 = about 0.28; impurity B isomer Y2 = about 0.31.<\/p>\n<p>System suitability: Reference solution (a):<\/p>\n<p>\u2014 the chromatogram obtained shows 2 peaks due to impurity B isomers Y1 and Y2.<\/p>\n<p>Limit:<\/p>\n<p>\u2014 sum of impurity B isomers Y1 and Y2: not more than the sum of the areas of the 2 principal peaks due to the iopromide in the chromatogram obtained with reference solution (c) (1.5 per cent).<\/p>\n<h3>Related substances<\/h3>\n<p>Thin-layer chromatography (2.2.27).<\/p>\n<p>Solvent mixture methanol R, water R (50:50 V\/V).<\/p>\n<p>Test solution: Dissolve 1.0 g of the substance to be examined in the solvent mixture and dilute to 10.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (a): Dilute 1.0 mL of the test solution to 100.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (b): Dilute 5.0 mL of reference solution (a) to 10.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (c): Dilute 2.0 mL of reference solution (a) to 10.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (d): Dilute 1.0 mL of reference solution (a) to 10.0 mL with the solvent mixture.<\/p>\n<p>Reference solution (e): Dissolve the contents of a vial of iopromide for system suitability 1 CRS (containing impurities B and E) in 50 \u03bcL of the solvent mixture.<\/p>\n<p>Reference solution (f): Dissolve the contents of a vial of iopromide for system suitability 2 CRS (containing impurities B, C, D and F) in 50 \u03bcL of the solvent mixture.<\/p>\n<p>Plates: TLC silica gel F254 plate R (2 plates).<\/p>\n<p>A. Mobile phase: concentrated ammonia R, water R, dioxan R (4:15:85 V\/V\/V).<\/p>\n<p>Application: 2 \u03bcL of the test solution and reference solutions (b), (d) and (e).<\/p>\n<p>Development: Over 3\/4 of the plate.<\/p>\n<p>Drying In a current of air, until complete evaporation of the solvents, then at 120 \u00b0C for 30 min.<\/p>\n<p>Detection: Examine immediately in ultraviolet light at 254 nm; expose to ultraviolet light for 2-5 min until the principal spots appear clearly as yellow spots, then spray with ferric chloride-ferricyanide-arsenite reagent R and examine immediately in daylight.<\/p>\n<p>Retardation factors Impurity B = about 0.26; iopromide = about 0.34; impurity E = about 0.41. System suitability Reference solution (e):<\/p>\n<p>\u2014 the chromatogram shows 3 clearly separated spots.<\/p>\n<p>Limits:<\/p>\n<p>\u2014 impurity E: any spot due to impurity E is not more intense than the principal spot in the chromatogram obtained with reference solution (b) (0.5 per cent);<\/p>\n<p>\u2014 unspecified impurities: any other spot is not more intense than the principal spot in the chromatogram obtained with reference solution (d) (0.10 per cent); disregard any spot due to impurity B.<\/p>\n<p>B. Mobile phase: anhydrous formic acid R, water R, methanol R, chloroform R (2:6:32:62 V\/V\/V\/V).<\/p>\n<p>Application: 2 \u03bcL of the test solution and reference solutions (a), (b) ,(c), (d) and (f).<\/p>\n<p>Development: Over 3\/4 of the plate.<\/p>\n<p>Drying: In a current of air, until complete evaporation of the solvents, then at 120 \u00b0C for 30 min.<\/p>\n<p>Detection: Examine immediately in ultraviolet light at 254 nm; expose to an ammonia vapour for 30 min, dry in a current of air for 10 min, then expose to ultraviolet light for 2-5 min until the principal spots appear clearly as yellow spots, then spray with ferric chloride-ferricyanide-arsenite reagent R and examine immediately in daylight.<\/p>\n<p>Retardation factors: Impurity C = about 0.23; impurity D = about 0.29; impurity B = about 0.36; iopromide = about 0.43; impurity F = about 0.71.<\/p>\n<p>System suitability: Reference solution (f):<\/p>\n<p>\u2014 the chromatogram shows 5 clearly separated spots.<\/p>\n<p>Limits:<\/p>\n<p>\u2014 impurity D: any spot due to impurity D is not more intense than the principal spot in the chromatogram obtained with reference solution (a) (1.0 per cent);<\/p>\n<p>\u2014 impurity C: any spot due to impurity C is not more intense than the principal spot in the chromatogram obtained with reference solution (b) (0.5 per cent);<\/p>\n<p>\u2014 impurity F: any spot due to impurity F is not more intense than the principal spot in the chromatogram obtained with reference solution (c) (0.2 per cent);<\/p>\n<p>\u2014 unspecified impurities: any other spot is not more intense than the principal spot in the chromatogram obtained with reference solution (d) (0.10 per cent); disregard any spot due to impurity B.<\/p>\n<h3>Isomer distribution<\/h3>\n<p>Liquid chromatography (2.2.29) as described in the test for impurity B with the following modifications.<\/p>\n<p>Calculate the percentage content of the isomer groups with reference to the total area of all the peaks due to the 4 iopromide isomers, using the chromatogram obtained with the test solution.<\/p>\n<p>Limits:<\/p>\n<p>\u2014 sum of iopromide isomers E1 and Z1: 40.0 per cent to 51.0 per cent;<\/p>\n<p>\u2014 sum of iopromide isomers E2 and Z2: 49.0 per cent to 60.0 per cent.<\/p>\n<h3>Free iodine<\/h3>\n<p>Dissolve 2.0 g in 20 mL of water R in a glass-stoppered test tube. Add 2 mL of dilute sulfuric acid R and 2 mL of toluene R, close and shake vigorously. The upper layer remains colourless (2.2.2, Method II).<\/p>\n<h3>Iodide<\/h3>\n<p>Maximum 2 ppm.<\/p>\n<p>Dissolve 10.0 g in 50 mL of carbon dioxide-free water R. Adjust to pH 3-4 adding about 0.15 mL of 0.1 M sulfuric acid.<\/p>\n<p>Titrate with 0.001 M silver nitrate. Determine the end-point potentiometrically (2.2.20) using a combined metal electrode.<\/p>\n<p>Not more than 0.15 mL of 0.001 M silver nitrate is required to reach the end-point.<\/p>\n<h3>Water (2.5.12)<\/h3>\n<p>Maximum 1.5 per cent, determined on 1.00 g.<\/p>\n<h3>Sulfated ash (2.4.14)<\/h3>\n<p>Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n<h3>Bacterial endotoxins (2.6.14)<\/h3>\n<p>Less than 1.0 IU\/g.<\/p>\n<h2>ASSAY<\/h2>\n<p>Liquid chromatography (2.2.29) as described in the test for impurity B with the following modifications.<\/p>\n<p>Injection: Test solution and reference solutions (a) and (b).<\/p>\n<p>Identification of the isomers: The 2 principal peaks in the chromatogram obtained with reference solution (a) are due to iopromide isomers Z1 and Z2. The 2 peaks that have an increased size in the chromatogram obtained with reference solution (b) in comparison to the chromatogram obtained with reference solution (a), are due to iopromide isomers E1 and E2.<\/p>\n<p>Relative retention: With reference to iopromide isomer Z2 (retention time = about 34 min): iopromide isomer E1 = about 0.70; iopromide isomer E2 = about 0.75; iopromide isomer Z1 = about 0.85.<\/p>\n<p>System suitability Reference solution (a):<\/p>\n<p>\u2014 resolution: minimum 2.0 between the peaks due to iopromide isomers Z1 and Z2.<\/p>\n<p>Calculate the percentage content of iopromide from the declared content of iopromide CRS and from the sum of the areas of all of the peaks due to isomer groups E and Z.<\/p>\n<h2>STORAGE<\/h2>\n<p>Protected from light.<\/p>\n<h2>IMPURITIES<\/h2>\n<p>Specified impurities A, B, C, D, E, F.<\/p>\n<p>Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) G, H.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16768\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-245-300x163.jpg\" alt=\"Iopromide \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-245-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-245-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-245-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-245.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>A. 5-amino-N,N\u2032-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methylbenzene-1,3-dicarboxamide,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16769\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-229-300x163.jpg\" alt=\"Iopromide \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-229-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-229-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-229-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-229.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>B. 5-(acetylamino)-N,N\u2032-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methylbenzene-1,3-dicarboxamide,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16770\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-209-300x163.jpg\" alt=\"Iopromide \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-209-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-209-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-209-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-209.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>C. N,N\u2032-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)amino]-2,4,6-triiodo-N-methylbenzene-1,3-dicarboxamide,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16772\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-169-300x163.jpg\" alt=\"Iopromide \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-169-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-169-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-169-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-169.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>D. N-(2,3-dihydroxypropyl)-N\u2032-[3-[[3-[(2,3-dihydroxypropyl)carbamoyl]-5-[(2,3-dihydroxypropyl)methylcarbamoyl]-2,4,6- triiodophenyl](methoxyacetyl)amino]-2-hydroxypropyl]-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylbenzene-1,3-dicarboxamide,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16773\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-132-300x163.jpg\" alt=\"Iopromide \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-132-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-132-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-132-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-132.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>E. 3-[[3-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodo-5-[(methoxyacetyl)amino]benzoyl]methylamino]-2-hydroxypropyl 3-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodo-5-[(methoxyacetyl)amino]benzoate,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16774\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-110-300x163.jpg\" alt=\"Iopromide \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-110-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-110-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-110-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-110.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>F. N\u2032-(2,3-dihydroxypropyl)-N-[[2-(hydroxymethyl)-2-methyl-1,3-dioxolan-4-yl]methyl]-2,4,6-triiodo-5- [(methoxyacetyl)amino]-N-methylbenzene-1,3-dicarboxamide,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16775\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-84-300x163.jpg\" alt=\"Iopromide \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-84-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-84-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-84-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-84.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>G. N\u2032-(2-chloro-3-hydroxypropyl)-N-(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylbenzene-1,3-dicarboxamide,<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-16776\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/9-62-300x163.jpg\" alt=\"Iopromide \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/9-62-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/9-62-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/9-62-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/9-62.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>H. 3-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodo-5-[(methoxyacetyl)amino]benzoic acid.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Ph. Eur. monograph 1753 ) C18H24I3N3O8 791 73334-07-3 Action and use Iodinated contrast medium. DEFINITION N,N\u2032-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylbenzene-1,3-dicarboxamide. Mixture of diastereoisomers and atropisomers. Content 97.0 per cent to 102.0 per cent (anhydrous substance). CHARACTERS Appearance White or slightly yellowish powder. Solubility Freely soluble in water and in dimethyl sulfoxide, practically insoluble in ethanol (96 per cent) and&#8230;<\/p>\n","protected":false},"author":4,"featured_media":16767,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-16478","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=16478"}],"version-history":[{"count":3,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16478\/revisions"}],"predecessor-version":[{"id":16778,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16478\/revisions\/16778"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/16767"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=16478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=16478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=16478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}